Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.36 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.36 |
| ▸ | ADA | P00813 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14946120 | 0.82 | ADORA2A (0.46) | AHCYADORA2AADORA2BDNMT1DNMT3B | |
| SCHEMBL14929097 | 0.82 | ADORA2A (0.46) | AHCYADORA2AADORA2BDNMT1DNMT3B | |
| SCHEMBL15930980 | 0.82 | ADORA2A (0.43) | AHCYADORA2AADORA2BDNMT1DNMT3B | |
| SCHEMBL16489873 | 0.82 | ADORA2A (0.43) | AHCYADORA2AADORA2BDNMT1DNMT3B | |
| SCHEMBL17809082 | 0.81 | AHCY (0.39) | AHCYADORA2AADORA2BADORA3DNMT1 | |
| SCHEMBL16477846 | 0.81 | AHCY (0.39) | AHCYADORA2AADORA2BADORA3DNMT1 | |
| SCHEMBL18852326 | 0.80 | ADORA2A (0.52) | AHCYADORA2AADORA2BADORA3DNMT1 | |
| SCHEMBL18852312 | 0.80 | ADORA2A (0.52) | AHCYADORA2AADORA2BADORA3DNMT1 | |
| SCHEMBL15868489 | 0.80 | ADORA2A (0.52) | AHCYADORA2AADORA2BADORA3DNMT1 | |
| SCHEMBL14946104 | 0.80 | ADORA2A (0.52) | AHCYADORA2AADORA2BADORA3DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | AHCY 722/4885ADORA2A 399/4885ADORA2B 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.